The PLX5622 Diaries
RBP4 antagonists are currently under medical demo to evaluate their efficacies in dealing with Stargardt disease (STGD, an inherited dysfunction that usually leads to eyesight decline in childhood or adolescence) [154]. The prolonged-expression efficacy, toxicity and pharmacokinetic property will definitely guide the appliance of RBP4 antagonists i